Surgery Partners (SGRY) Projected to Post Earnings on Monday

Surgery Partners (NASDAQ:SGRY) is expected to release its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of $0.08 per share and revenue of $777.77 million for the quarter. Surgery Partners has set its FY 2025 guidance at EPS.

Surgery Partners (NASDAQ:SGRY) last released its earnings results on Monday, March 3rd. The company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.01. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. The firm had revenue of $864.40 million during the quarter, compared to the consensus estimate of $828.09 million. On average, analysts expect Surgery Partners to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Surgery Partners Stock Down 2.1 %

SGRY opened at $22.20 on Friday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.66 and a current ratio of 1.80. The company has a market capitalization of $2.85 billion, a PE ratio of -46.25, a P/E/G ratio of 19.21 and a beta of 1.96. The stock’s fifty day moving average is $22.61 and its 200-day moving average is $23.48. Surgery Partners has a one year low of $19.50 and a one year high of $33.97.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on SGRY shares. Benchmark restated a “buy” rating and set a $35.00 price objective on shares of Surgery Partners in a research report on Monday, April 21st. Royal Bank of Canada reissued an “outperform” rating and set a $35.00 price target on shares of Surgery Partners in a research report on Tuesday, March 25th. Finally, Macquarie decreased their target price on shares of Surgery Partners from $34.00 to $33.00 and set an “outperform” rating for the company in a research note on Tuesday, March 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.75.

Insider Buying and Selling

In other news, CFO David T. Doherty sold 6,733 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $24.02, for a total transaction of $161,726.66. Following the completion of the transaction, the chief financial officer now owns 150,868 shares of the company’s stock, valued at approximately $3,623,849.36. This represents a 4.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Marissa Brittenham sold 3,156 shares of Surgery Partners stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $24.09, for a total value of $76,028.04. Following the sale, the insider now directly owns 63,408 shares in the company, valued at approximately $1,527,498.72. This trade represents a 4.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.30% of the stock is owned by insiders.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.